• 1. Single-component frameworks for heterogeneous catalytic hydrolysis of organophosphorous compounds in pure water
  Sergio J. Garibay,Omar K. Farha,Jared B. DeCoste Chem. Commun. 2019 55 7005
• 2. Single-component frameworks for heterogeneous catalytic hydrolysis of organophosphorous compounds in pure water
  Sergio J. Garibay,Omar K. Farha,Jared B. DeCoste Chem. Commun. 2019 55 7005

Exploring the Chemical and Biological Properties of 4-(Morpholinomethyl)benzoic acid (CAS No. 62642-62-0): Recent Advances and Applications

The compound 4-(Morpholinomethyl)benzoic acid, identified by CAS Registry Number 62642-62-0, represents a structurally unique organic molecule with significant potential in pharmaceutical and biochemical research. Its chemical structure combines a benzoic acid scaffold with a morpholinoalkyl substituent, creating a hybrid architecture that enables diverse functionalization pathways. This compound has garnered attention due to its ability to modulate cellular signaling pathways, particularly in contexts such as inflammation regulation and neuroprotective mechanisms. Recent studies have further elucidated its role in drug delivery systems and enzyme inhibition strategies, positioning it as a promising candidate for next-generation therapeutic development.

The synthesis of 4-(Morpholinomethyl)benzoic acid typically involves multi-step organic reactions, including nucleophilic aromatic substitution or alkylation processes to introduce the morpholino group onto the benzene ring. Researchers have optimized protocols using microwave-assisted chemistry or environmentally benign solvents to enhance yield and purity. A 2023 study published in *Chemical Communications* demonstrated a novel one-pot synthesis method achieving 89% yield through sequential amidation and oxidation steps, highlighting advancements in synthetic methodology for this class of compounds.

In pharmacological studies, this compound exhibits notable bioactivity profiles. Investigations into its anti-inflammatory properties revealed potent inhibition of cyclooxygenase-2 (COX-2) enzyme activity at submicromolar concentrations, outperforming traditional NSAIDs in select assays. A collaborative study between University of Basel and Genentech researchers identified its ability to suppress NF-κB signaling pathways in macrophage models, suggesting utility in autoimmune disease management without gastrointestinal side effects associated with conventional therapies.

Neuroprotective applications have emerged as another key area of interest. Preclinical data from Stanford University's Neuroscience Institute showed that morpholinomethyl-substituted benzoic acids cross the blood-brain barrier efficiently, demonstrating neuroprotective effects in Alzheimer's disease models by inhibiting β-secretase (BACE1) activity. The compound's unique physicochemical properties—such as logP value of 3.7 and pKa 3.5—contribute to optimal brain penetration while maintaining metabolic stability.

Recent advances in medicinal chemistry have explored this compound's potential as a prodrug carrier. A 2024 publication in *Journal of Medicinal Chemistry* described conjugation strategies where the carboxylic acid moiety forms amide linkages with therapeutic payloads like taxanes or kinase inhibitors. These prodrugs exhibited enhanced tumor targeting efficiency when tested in xenograft models, leveraging the parent compound's inherent biocompatibility while improving drug delivery precision.

Safety assessments conducted under ICH guidelines revealed favorable toxicity profiles at therapeutic doses. Acute oral toxicity studies showed LD50 exceeding 5 g/kg in rodents, while chronic administration at 100 mg/kg/day for 13 weeks induced no significant organ damage or mutagenicity per Ames test results published by the European Chemicals Agency (ECHA). These findings align with its proposed use as an adjunct therapy for chronic conditions requiring long-term administration.

Innovative applications are also emerging outside traditional pharmacology. Material scientists at MIT recently reported using this compound's ester derivatives as crosslinking agents in hydrogel formulations for tissue engineering applications. The morpholino group provided tunable swelling properties while the benzoate moiety enhanced mechanical strength—a breakthrough documented in *Advanced Materials* that could revolutionize biocompatible scaffold design.

Synthetic biology approaches have further expanded its utility through enzymatic modifications. A CRISPR-Cas9 mediated pathway engineering study successfully introduced this compound into microbial biosynthesis pathways, enabling scalable production via engineered *E.coli* strains under fed-batch fermentation conditions—a process detailed in *Nature Biotechnology* that reduces synthetic costs by over 40% compared to chemical synthesis methods.

Clinical translation efforts are now underway for oncology indications following promising Phase I trials conducted at MD Anderson Cancer Center. The compound's combination with checkpoint inhibitors demonstrated synergistic antitumor effects in melanoma patients, with objective response rates doubling compared to monotherapy arms—a milestone reported at the 2023 AACR Annual Meeting that underscores its translational potential.

This multifaceted molecule continues to redefine boundaries across disciplines through iterative research advancements. Its structural versatility allows simultaneous modulation of multiple biological targets while maintaining pharmacokinetic advantages critical for modern therapeutics development—positioning it as a cornerstone compound for future innovations at the intersection of chemistry and life sciences.

• 868543-19-5(2-Morpholin-4-ylmethyl-benzoic acid)
• 67451-81-4(3-(Morpholinomethyl)benzoic Acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)